Crysvita - direct healthcare professional communication (DHPC)

burosumab
DHPCVeterinary

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

Programmist

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Dokumendid

Direct healthcare professional communication (DHPC): Crysvita (burosumab): Risk of severe hypercalcaemia

English (EN) (173.69 KB - PDF)

Esmakordselt avaldatud:
Vaata

Key facts

Medicine name
Crysvita
Active substance
burosumab
Therapeutic area (MeSH)
  • Hypophosphatemia, Familial
  • Hypophosphatemic Rickets, X-Linked Dominant
  • Osteomalacia
Procedure number
EMAVR0000261369
Regulatory outcome
Variation
DHPC type
Adverse event
Human ATC codes
M05BX05
Dissemination date

Share this page